Radiopharma Partnerships Scale Radspherin manufacturing through radiopharma partnerships and contract laboratories, leveraging existing collaborations such as ARTBIO to accelerate supply for phase two trials and international sites.

Trial Collaboration Expansion Enable faster site activation and patient recruitment by courting leading academic medical centers and CROs for phase two trials, offering trial infrastructure and support to expand global enrollment.

Adoption Pathways Drive clinical adoption by targeting surgical oncology, gastro oncology, and nuclear medicine departments with a clear value proposition of a localized alpha dose to destroy residual micrometastases in the abdominal cavity.

Market Access Readiness Prepare for market entry by aligning with payers, regulators, and regional distributors, using merger maturity and leadership signals to secure strategic partnerships and funding for international expansion.

Differentiated Value Differentiate on receptor independent alpha radiation therapy delivered within the abdominal cavity, highlighting a niche with high unmet need in peritoneal metastases to attract hospital networks seeking innovative oncology options.